RASAL2 and prostate cancer: In this study, for the first time, we demonstrated that RASAL2 was upregulated in prostate cancer and associated with the cell cycle, tumour growth and poor disease prognosis, in which the PI3K/AKT signalling pathway and cyclin D1 expression played an important role.